Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. LaPelusa M, et al. Among authors: kaseb ao. Oncology. 2024 Oct 18:1-8. doi: 10.1159/000541250. Online ahead of print. Oncology. 2024. PMID: 39427654 Free article.
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.
Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang J, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Gu L, et al. Among authors: kaseb ao. bioRxiv [Preprint]. 2023 Mar 6:2023.03.05.531188. doi: 10.1101/2023.03.05.531188. bioRxiv. 2023. Update in: Proc Natl Acad Sci U S A. 2023 May 9;120(19):e2300706120. doi: 10.1073/pnas.2300706120 PMID: 36945365 Free PMC article. Updated. Preprint.
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Chamseddine S, et al. Among authors: kaseb ao. J Immunother Precis Oncol. 2024 Nov 1;7(4):255-262. doi: 10.36401/JIPO-24-6. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524465 Free PMC article.
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Mohamed YI, et al. Among authors: kaseb ao. Cancer Biomark. 2024;41(1):83-91. doi: 10.3233/CBM-230431. Cancer Biomark. 2024. PMID: 39269823 Free PMC article.
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, Cristini V, Ozpolat B, Calin GA, Wang Z. Dogra P, et al. Among authors: kaseb ao. Mol Cancer. 2024 Aug 2;23(1):156. doi: 10.1186/s12943-024-02060-5. Mol Cancer. 2024. PMID: 39095771 Free PMC article.
144 results